A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Abstract

This phase 2 trial of patients with NASH showed that semaglutide treatment resulted in a significantly higher percentage of patients with NASH resolution than placebo. The trial did not show a significant improvement in fibrosis.

Citation
Newsome PN, Buchholtz K, Cusi K, et al. N Engl J Med 2020; epub ahead of press.